JW Lifescience Corporation (KRX:234080)

JW Lifescience Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	248,297	222,478	206,860	188,931	169,817	183,521
Other Revenue	0	-	-	-0	-0	-
Revenue	248,297	222,478	206,860	188,931	169,817	183,521
Revenue Growth (YoY)	12.19%	7.55%	9.49%	11.26%	-7.47%	7.81%
Cost of Revenue	179,496	165,010	154,507	140,972	120,788	124,243
Gross Profit	68,800	57,468	52,353	47,959	49,029	59,278
Selling, General & Admin	26,126	16,518	15,100	13,358	12,908	13,180
Research & Development	5,038	4,030	5,161	5,737	6,242	5,195
Amortization of Goodwill & Intangibles	1,085	278.99	403.54	744.89	493.83	482.3
Other Operating Expenses	324.93	262.41	161.56	159.04	162.39	199.85
Operating Expenses	33,547	21,610	21,491	20,870	20,612	19,827
Operating Income	35,254	35,858	30,862	27,089	28,417	39,451
Interest Expense	-2,061	-2,061	-2,693	-3,092	-1,281	-2,609
Interest & Investment Income	1,506	1,506	1,130	1,087	130.36	1,427
Earnings From Equity Investments	12,083	10,392	6,489	-4,921	-4,780	-7,129
Currency Exchange Gain (Loss)	-2,570	-2,570	-651.41	329.73	-149.04	-150.86
Other Non Operating Income (Expenses)	15,294	15,864	-1,251	296.71	-3,772	-8,197
EBT Excluding Unusual Items	59,506	58,989	33,886	20,789	18,565	22,791
Gain (Loss) on Sale of Investments	46.49	46.49	-	-	-	-
Gain (Loss) on Sale of Assets	4.9	4.9	-	-	1.71	-4.14
Asset Writedown	-14.09	-14.09	-166.58	-7.42	-279.65	-46.75
Other Unusual Items	-	-	-10.72	-	-	-
Pretax Income	59,544	59,027	33,708	20,782	18,287	22,740
Income Tax Expense	11,955	15,039	5,564	5,821	5,373	5,440
Net Income	47,589	43,988	28,144	14,961	12,914	17,300
Net Income to Common	47,589	43,988	28,144	14,961	12,914	17,300
Net Income Growth	65.14%	56.29%	88.11%	15.86%	-25.36%	-21.14%
Shares Outstanding (Basic)	15	15	15	15	16	16
Shares Outstanding (Diluted)	15	15	15	15	16	16
Shares Change (YoY)	-0.03%	-	-	-0.61%	-1.61%	-
EPS (Basic)	3074.03	2840.74	1817.55	966.21	828.84	1092.55
EPS (Diluted)	3074.03	2840.74	1817.55	966.00	828.84	1092.55
EPS Growth	65.19%	56.29%	88.15%	16.55%	-24.14%	-21.14%
Free Cash Flow	27,530	40,383	29,421	6,049	11,189	30,824
Free Cash Flow Per Share	1778.32	2607.96	1900.03	390.67	718.13	1946.62
Dividend Per Share	500.000	500.000	500.000	500.000	500.000	500.000
Gross Margin	27.71%	25.83%	25.31%	25.38%	28.87%	32.30%
Operating Margin	14.20%	16.12%	14.92%	14.34%	16.73%	21.50%
Profit Margin	19.17%	19.77%	13.61%	7.92%	7.60%	9.43%
Free Cash Flow Margin	11.09%	18.15%	14.22%	3.20%	6.59%	16.80%
EBITDA	52,637	51,595	46,393	42,045	41,661	51,697
EBITDA Margin	21.20%	23.19%	22.43%	22.25%	24.53%	28.17%
D&A For EBITDA	17,383	15,737	15,531	14,956	13,245	12,246
EBIT	35,254	35,858	30,862	27,089	28,417	39,451
EBIT Margin	14.20%	16.12%	14.92%	14.34%	16.73%	21.50%
Effective Tax Rate	20.08%	25.48%	16.51%	28.01%	29.38%	23.92%
Advertising Expenses	-	1,564	1,731	1,605	1,666	1,039

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.